health
STAT+: Talawar bets bispecific approach can shake up eczema market
Why this matters: health reporting relevant to everyday decisions and well-being.
Want to stay on top of the science and politics driving biotech today?&#x A0;Sign up&#x A0;to get our biotech newsletter in your inbox. Today: We look at the unseemly side of scrutiny of Chinese biotech, have a SPAC for a bispecific maker,&#x A0;and Moderna’s m RNA ambitions enter a new phase despite years of setbacks. Plus: Clive Meanwell sees AI’s biggest opportunity in the macro&#x A0;processes of biotech drug design, as opposed to the bespoke making of molecules.Continue to STAT+ to read the full story…
Article preview — originally published by STAT News. Full story at the source.
Read full story on STAT News →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from STAT News alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop